Literature DB >> 18043544

Workshop on the production, application and clinical translation of ''non-standard'' PET nuclides: a meeting report.

J S Lewis1, M J Welch, L Tang.   

Abstract

A one-day satellite workshop was organized to coincide with the 17(th) International Symposium on Radiopharmaceutical Sciences held in Aachen, Germany, April 30-May 4, 2007. The workshop, ''Production and application of non-standard' PET nuclides'', was held on Sunday April 29, 2007 at the Eurogress Aachen and was organized by J. Lewis, PhD, L. Tang, and M. Welch, PhD. The workshop was designed for the radiopharmaceutical community discussing the production, use and dissemination of the ''non-standard'' PET nuclides. The definition of ''non-standard'' positron emission tomography (PET) nuclides included (45)Ti, (60)Cu, (61)Cu, (64)Cu, (66)Ga, (72)As, (74)As, (76)Br, (86)Y, (89)Zr, (94)mTc and (124)I. The workshop was supported by the grant Research Resource for Cancer Applications (R24 CA86307) funded by the National Cancer Institute at the National Institutes of Health. The workshop was attended by over 110 scientists and engineers from over 20 countries from all over the world and was designed with an open forum style to allow for discussions and interactions by all participants. All of the invited speakers were asked to make a contribution to this edition of the Quarterly Journal of Nuclear Medicine. The individual articles following this introduction are reviews of their area of expertise and the current state-of-the-art. This introduction briefly describes the role of the workshop, the aims and the general outcome. Also, the translation of these nuclides to the clinic, perhaps the most important goal of this work is discussed in this introductory article.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18043544      PMCID: PMC4412264     

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  22 in total

1.  A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.

Authors:  R T O'Donnell; G L DeNardo; D L Kukis; K R Lamborn; S Shen; A Yuan; D S Goldstein; C E Carr; G R Mirick; S J DeNardo
Journal:  J Nucl Med       Date:  1999-12       Impact factor: 10.057

2.  64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.

Authors:  C J Anderson; F Dehdashti; P D Cutler; S W Schwarz; R Laforest; L A Bass; J S Lewis; D W McCarthy
Journal:  J Nucl Med       Date:  2001-02       Impact factor: 10.057

3.  67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.

Authors:  G L DeNardo; D L Kukis; S Shen; D A DeNardo; C F Meares; S J DeNardo
Journal:  Clin Cancer Res       Date:  1999-03       Impact factor: 12.531

4.  Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography.

Authors:  F Rösch; H Herzog; C Plag; B Neumaier; U Braun; H W Müller-Gärtner; G Stöcklin
Journal:  Eur J Nucl Med       Date:  1996-08

5.  Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.

Authors:  Susanne M Eschmann; Gerald Reischl; Kilian Bilger; Juergen Kupferschläger; Marcel H Thelen; Bernhard M Dohmen; Hariolf Besenfelder; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-27       Impact factor: 9.236

6.  Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.

Authors:  G L Denardo; S J Denardo; D L Kukis; R T O'Donnell; S Shen; D S Goldstein; L A Kroger; Q Salako; D A Denardo; G R Mirick; L F Mausner; S C Srivastava; C F Meares
Journal:  Anticancer Res       Date:  1998 Jul-Aug       Impact factor: 2.480

7.  Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.

Authors:  Andreas Helisch; Gregor J Förster; Helmut Reber; Hans-Georg Buchholz; Rudolf Arnold; Burkhard Göke; Matthias M Weber; Bertram Wiedenmann; Stanislas Pauwels; Ulrike Haus; Hakim Bouterfa; Peter Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-03       Impact factor: 9.236

8.  Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography.

Authors:  R J Ott; D Tait; M A Flower; J W Babich; R M Lambrecht
Journal:  Br J Radiol       Date:  1992-09       Impact factor: 3.039

9.  PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma.

Authors:  S M Larson; K S Pentlow; N D Volkow; A P Wolf; R D Finn; R M Lambrecht; M C Graham; G Di Resta; B Bendriem; F Daghighian
Journal:  J Nucl Med       Date:  1992-11       Impact factor: 10.057

10.  Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report.

Authors:  L S Freudenberg; G Antoch; R Görges; J Knust; R Pink; W Jentzen; J F Debatin; W Brandau; A Bockisch; J Stattaus
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

View more
  11 in total

Review 1.  PET tracers based on Zirconium-89.

Authors:  Yin Zhang; Hao Hong; Weibo Cai
Journal:  Curr Radiopharm       Date:  2011-04

Review 2.  PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques.

Authors:  Habib Zaidi; Issam El Naqa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-25       Impact factor: 9.236

Review 3.  Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.

Authors:  Egesta Lopci; Arturo Chiti; Maria Rita Castellani; Giovanna Pepe; Lidija Antunovic; Stefano Fanti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

4.  Copper-64 Radiopharmaceuticals for Oncologic Imaging.

Authors:  Jason P Holland; Riccardo Ferdani; Carolyn J Anderson; Jason S Lewis
Journal:  PET Clin       Date:  2009-01

Review 5.  Whole animal imaging.

Authors:  Gurpreet Singh Sandhu; Luis Solorio; Ann-Marie Broome; Nicolas Salem; Jeff Kolthammer; Tejas Shah; Chris Flask; Jeffrey L Duerk
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010 Jul-Aug

6.  64Cu Core-labeled nanoparticles with high specific activity via metal-free click chemistry.

Authors:  Dexing Zeng; Nam S Lee; Yongjian Liu; Dong Zhou; Carmen S Dence; Karen L Wooley; John A Katzenellenbogen; Michael J Welch
Journal:  ACS Nano       Date:  2012-05-08       Impact factor: 15.881

7.  Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.

Authors:  Carolyn J Anderson; Riccardo Ferdani
Journal:  Cancer Biother Radiopharm       Date:  2009-08       Impact factor: 3.099

Review 8.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

9.  An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix.

Authors:  Jason S Lewis; Richard Laforest; Farrokh Dehdashti; Perry W Grigsby; Michael J Welch; Barry A Siegel
Journal:  J Nucl Med       Date:  2008-06-13       Impact factor: 10.057

10.  A novel technology for the imaging of acidic prostate tumors by positron emission tomography.

Authors:  Amy L Vāvere; Gráinne B Biddlecombe; William M Spees; Joel R Garbow; Dayanjali Wijesinghe; Oleg A Andreev; Donald M Engelman; Yana K Reshetnyak; Jason S Lewis
Journal:  Cancer Res       Date:  2009-05-05       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.